CRP and inflammatory bowel disease: Thus, this highlighted the use of fecal calprotectin in assessing mucosal healing in IBD patients [16]. Several recent studies have compared the C-reactive protein levels in both CD and UC, respectively, and have demonstrated that the concentration levels of CRP decreased in those treated with infliximab; this result makes CRP an effective tool in both treatment efficacy and monitoring flare-ups [17].